Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

• Status: Active, not recruiting
• Trial end date: 2022-08-25

Summary

This phase II clinical trial studies how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Monoclonal antibodies, such as alemtuzumab, may interfere with the ability of cancer cells to grow and spread. Giving more than one drug (combination chemotherapy) and giving dasatinib together with chemotherapy may kill more cancer cells.

• Phase: Phase 2

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: 6-Mercaptopurine; Alemtuzumab; Antibodies; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; BB 1101; Calcium; Calcium, Dietary; Cyclophosphamide; Cytarabine; Dasatinib; Daunorubicin; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Etoposide; Etoposide phosphate; Fludarabine; Fludarabine phosphate; Folic Acid; Immunoglobulins; Lenograstim; Leucovorin; Levoleucovorin; Mechlorethamine; Melphalan; Mercaptopurine; Methotrexate; Nitrogen Mustard Compounds; Tacrolimus; Vincristine